Company Overview
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.
Company Information
- CEO
- Jacob Thaysen
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 8970
Contact Information
- Website
- https://www.illumina.com
- Address
- 5200 Illumina Way
- Country
- US
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 15.45B market capitalization
- Trading Volume: 1.16M shares traded today
- Price Range: 52-week range of $68.70 - $156.66
- Exchange: Listed on NASDAQ Global Select
Financial Metrics
Market Analysis for Illumina, Inc.
Illumina, Inc. (ILMN) operates in the Medical - Diagnostics & Research industry within the Healthcare sector. With a current market capitalization of 15.45B, the company represents a significant player in its market. The stock is currently trading at $100.53 with a positivedaily change of 0.42%.
The company's 8970 employee base and presence on the NASDAQ Global Selectexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of 12.73, beta of 1.37, and 52-week price range from $68.70 to $156.66when evaluating investment opportunities.
Why Invest in Illumina, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Select)
- • Experienced leadership under Jacob Thaysen
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.